Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $52.12 USD
Change Today +2.13 / 4.26%
Volume 84.8K
BSTC On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

biospecifics technologies (BSTC) Snapshot

Open
$49.73
Previous Close
$49.99
Day High
$52.23
Day Low
$49.50
52 Week High
08/3/15 - $72.07
52 Week Low
09/2/14 - $29.99
Market Cap
356.9M
Average Volume 10 Days
105.6K
EPS TTM
$1.03
Shares Outstanding
6.8M
EX-Date
--
P/E TM
50.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOSPECIFICS TECHNOLOGIES (BSTC)

biospecifics technologies (BSTC) Related Bloomberg News

View More Bloomberg News

biospecifics technologies (BSTC) Related Businessweek News

No Related Businessweek News Found

biospecifics technologies (BSTC) Details

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of Dupuytren’s contracture and Peyronie’s disease under the XIAFLEX brand in Canada, Australia, Brazil, and Mexico, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, human lipoma, canine lipoma, and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Auxilium Pharmaceuticals, Inc. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.

5 Employees
Last Reported Date: 03/16/15
Founded in 1957

biospecifics technologies (BSTC) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2014.

biospecifics technologies (BSTC) Key Developments

BioSpecifics Technologies Corp. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

BioSpecifics Technologies Corp. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company’s total revenues were $4,714,975 against $2,642,056 a year ago. Operating income was $2,662,974 against $865,210 a year ago. Income before income tax expense was $2,681,456 against $883,011 a year ago. Net income was $1,757,204 against $577,966 a year ago. Diluted net income per share was $0.24 against $0.08 a year ago. For the six months, the company’s total revenues were $10,321,429 against $5,399,657 a year ago. Operating income was $6,226,841 against $1,993,802 a year ago. Income before income tax expense was $6,263,676 against $2,023,402 a year ago. Net income was $4,088,104 against $1,331,955 a year ago. Diluted net income per share was $0.57 against $0.19 a year ago.

BioSpecifics Technologies Corp. to Report Q2, 2015 Results on Aug 10, 2015

BioSpecifics Technologies Corp. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 10, 2015

BioSpecifics Technologies Corp., Q2 2015 Earnings Call, Aug 11, 2015

BioSpecifics Technologies Corp., Q2 2015 Earnings Call, Aug 11, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSTC:US $52.12 USD +2.13

BSTC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BSTC.
View Industry Companies
 

Industry Analysis

BSTC

Industry Average

Valuation BSTC Industry Range
Price/Earnings 50.6x
Price/Sales 18.5x
Price/Book 9.6x
Price/Cash Flow 48.2x
TEV/Sales 17.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOSPECIFICS TECHNOLOGIES, please visit www.biospecifics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.